Shots:
- The US FDA has approved TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with challenging cases of atrial fibrillation (AFib)
- Approval was based on the results from Abbott’s FlexPulse IDE study, with data recently presented at the ESC’26 & simultaneously published in EPEuropace, showing favorable safety & effectiveness outcomes in pts with paroxysmal AFib
- TactiFlex Duo delivers tailored therapy using both pulsed field ablation & radiofrequency energy, and integrates with Abbott’s EnSite X EP System to create detailed 3D heart maps to help identify & treat arrhythmia sources
Ref: PRnewswire | Image: Abbott | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
